{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Dose interruption, dose reduction or discontinuation of lenalidomide due to toxicity, GVHD or disease progression","groups":[{"description":"Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity.\n\nlenalidomide: Given PO","id":"OG000","title":"Treatment (Lenalidomide)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients enrolled on the trial who received lenalidomide treatment.","reportingStatus":"POSTED","timeFrame":"Up to 9 years","title":"Number of Patients Requiring Dose Interruption, Dose Reduction or Discontinuance of Lenalidomide","type":"SECONDARY","unitOfMeasure":"Participants"}